Following validation that the peptide pools could expand both SARS-CoV-2-specific CD4+ and CD8+ T cells in the laboratory from convalescent donor blood samples collected 12 months after infection (S6 Fig), we generated two clinical-grade lots of SARS-CoV-2-specific T cells (THI-COV-002 and THI-COV-003) under Good Manufacturing Practice conditions at Q-Gen Cell Therapeutics. The gene discussed is CD8A; the disease is infection.